ThermoGenesis Holdings, Inc

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, CAR-Txpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.

ThermoGenesis Holdings, Inc. (THMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ThermoGenesis Holdings, Inc. (THMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

RANCHO CORDOVA, Calif., Sept. 14, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company was awarded a $250,000 Phase I Small Business Innovation Research (SBIR) grant to develop and test the single-use sterile cell processing disposable, that will be used by the fully automated Quintessence System.

ThermoGenesis Awarded NIH SBIR Phase I Grant to Develop Key Cell Processing Disposable for Quintessence Automated manufacturing of Gene-engineered Autologous Cell (GEAC) Therapies

RANCHO CORDOVA, Calif., Sept. 7, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D.

Thermogenesis Holdings to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Thermogenesis Holdings, Inc. (THMO) on Q2 2021 Results - Earnings Call Transcript

ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -111.11% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ThermoGenesis Holdings, Inc. (THMO) Reports Q2 Loss, Tops Revenue Estimates

Shares of ThermoGenesis Holdings (NASDAQ:THMO) decreased 2.7% after the company reported Q2 results. Quarterly Results Earnings per share rose 62.75% over the past year to ($0.38), which missed the estimate of ($0.18).

Recap: ThermoGenesis Holdings Q2 Earnings

RANCHO CORDOVA, Calif., Aug. 12, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2021 and provided a corporate strategic update.

ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2021, and Provides Corporate Update

ThermoGenesis Holdings, Inc. (THMO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

RANCHO CORDOVA, Calif., Aug. 5, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2021 and provide a corporate strategic update on Thursday, August 12, 2021, after the close of trading.

ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2021 and Provide a Corporate Strategic Update

Jerash holdings (US) Inc

Patterson Companies

Sabre

Upwork Inc

PDCO, SABR, JRSH, UPWK, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2021

New Strong Sell Stocks for July 2nd

Aptorum Group Ltd - Ordinary Shares - Class A

Comstock Mining

Which Reddit penny stocks are investors watching right now? Check these 3 out The post 3 Penny Stocks on Reddit Making Big Waves Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks on Reddit Making Big Waves Right Now

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q1 2021 Results - Earnings Call Transcript

Shares of ThermoGenesis Holdings (NASDAQ:THMO) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 85.59% year over year to ($0.16), which missed the estimate of ($0.13).

Recap: ThermoGenesis Holdings Q1 Earnings

RANCHO CORDOVA, Calif., May 13, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2021 and provided a corporate strategic update.

ThermoGenesis Holdings Announces Financial Results for the First Quarter Ended March 31, 2021 and Provides Corporate Update

Prometheus Biosciences

Vyant Bio

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

3 Short Squeeze Candidates In The Health Care Sector

RANCHO CORDOVA, Calif., May 6, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2021 and provide a corporate strategic update on Thursday, May 13, 2021, after the close of trading.

ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2021 and Provide a Corporate Strategic Update

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q4 2020 Results - Earnings Call Transcript

RANCHO CORDOVA, Calif., March 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the year ended December 31, 2020 and provided a corporate strategic update.

ThermoGenesis Holdings Announces 2020 Year End Financial Results and Provides Corporate Update

RANCHO CORDOVA, Calif., March 10, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2020 and provide a corporate strategic update on Wednesday, March 17, 2021, after the close of trading.

ThermoGenesis Holdings to Announce Financial Results for the Fourth Quarter Ended December 31, 2020 and Provide a Corporate Strategic Update

RANCHO CORDOVA, Calif., Feb. 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. ("ThermoGenesis" or the "Company") (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company will kick off a year...

ThermoGenesis Holdings Begins a Year of Celebration of its 35th Anniversary in the Cell Banking and Cell Therapy Industry

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q3 2020 Results - Earnings Call Transcript

RANCHO CORDOVA, Calif., Nov. 12, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the third quarter ended September 30,...

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2020 and Provides Corporate Update

ADMA Biologics

Cerus

Grifols, S.A.

Kamada

Liminal BioSciences

Sonnet BioTherapeutics

T2 Biosystems

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients.

These Plasma Stocks Are Surging After FDA's Convalescent EUA

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q2 2020 Results - Earnings Call Transcript

RANCHO CORDOVA, Calif., Aug. 14, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc.

News for ThermoGenesis Holdings, Inc Stock (THMO)